Kestra Medical Technologies (KMTS) Cash & Equivalents (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported Cash & Equivalents for 3 consecutive years, with $262.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 10.36% year-over-year to $262.2 million; the TTM figure through Apr 2026 stood at $262.2 million (up 10.36% YoY), while the FY2026 annual figure was $262.2 million, up 10.36% from the prior year.
• Cash & Equivalents slipped to $262.2 million in Q2 2026 per KMTS's latest filing, from $291.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $291.3 million in Q1 2026 and bottomed at $8.2 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $142.3 million across 3 years, with a median of $137.7 million in 2024.
• Annual changes were most pronounced in 2025 — Cash & Equivalents jumped 2780.29% — and 2026, when it increased 10.36%.
• Kestra Medical Technologies' Cash & Equivalents stood at $76.9 million in 2024, then soared by 128.07% to $175.4 million in 2025, then surged by 49.47% to $262.2 million in 2026.
• Business Quant data shows KMTS's Cash & Equivalents at $262.2 million in Q2 2026, $291.3 million in Q1 2026, and $175.4 million in Q4 2025.